CAChristian Brix Folsted Andersen

Christian Brix Folsted Andersen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Brix Folsted Andersen has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autoantibodies From Connective Tissue Diseases Penetrate Cells and Exert Functional Properties

    by Aurélien Chepy, Celine Thiesen, Marie-Elise Martel, Maithri Aspari, Solange Vivier, Jakob Hauge Mikkelsen, Emilia Holm, Sören Magnus Morische, Esben Næser, Julien Sottiaux, et al.

    Antinuclear antibodies (ANAs) are a hallmark of connective tissue diseases (CTDs) and serve as robust diagnostic biomarkers. Because their cognate antigens are intracellular, ANAs have long been considered non-pathogenic in CTDs. Here, using systemic sclerosis (SSc) associated anti-topoisomerase I antibodies (ATAs) as a model, we provide data challenging this view. We show that ANAs enter living cells, accumulate in nuclei, and engage their intracellular antigen. Nuclear ATAs inhibit topoisomerase I enzymatic activity, induces DNA damage, fibrosis, and, through the STING pathway, activates type I interferon production. We further identify neonatal Fc receptor (FcRn)-dependent intracellular trafficking as a key determinant of ANAs nuclear access and demonstrate that pharmacological FcRn blockade impairs ATAs functionality. These findings reveal a previously unrecognized intracellular effector function of ANAs and establish a mechanistic framework by which ANAs may directly contribute to tissue injury in CTDs.

  • Effects of Prednisolone Administration on Clock Gene Expression and Indices of Circadian Rhythms in Healthy Human Males

    by Simon Bøggild Hansen, Jelena Skaaning Stankovic Frederiksen, Andreas Lodberg, Mathias Flensted Poulsen, Christian Brix Folsted Andersen, Henrik Oster, Niels Jessen, Jens Otto Lunde Jørgensen

    Objective: To investigate the impact of glucocorticoid (GC) exposure on clock gene expression in human skeletal muscle and fat, circadian variations in peripheral interstitial glucose levels, blood pressure, total and bioactive GC levels, and sleep quality. Methods: This randomized double-blind crossover trial included 10 healthy male individuals aged 18 to 34 years. Prednisolone (12.5 mg)/placebo was given in random order twice daily at 07:00 hours and 19:00 hours for 5 days with a 6-week washout. Results: Prednisolone suppressed endogenous circadian cortisol levels while mean ± SD area under the curve (AUC) serum free GC activity (µmol/L*min) increased 4.5-fold (121.9 ± 30.8 [prednisolone] vs 27.2 ± 8.3 [placebo], P < .001). Prednisolone significantly abrogated the normal approximately 3-fold morning:evening variation in mRNA expression of 4 clock genes—BMAL1, NPAS2, PER3, and REV-ERB-β—in both adipose tissue and skeletal muscle. Prednisolone also increased nocturnal levels of interstitial glucose 67% (95% CI 36%-97%, P < .001) more than diurnal levels. Prednisolone increased mean ± SD nocturnal systolic blood pressure (mmHg) (123 ± 14 [prednisolone] vs 116 ± 7 [placebo], P = .05) and reduced mean ± SD sleep efficiency (%) (84% ± 4% [prednisolone] vs 87% ± 5% [placebo], P = .04) Conclusions: (1) Prednisolone abrogates the temporal pattern of clock gene expression in human skeletal muscle and adipose tissue. (2) This is accompanied by perturbations of circadian variations in interstitial glucose levels, blood pressure, as well as sleep quality. (3) We hypothesize that adverse effects of high-dose prednisolone treatment are partly mediated by disrupted clocks in metabolic tissues.


  • STING signals to NF-κB from late endolysosomal compartments using IRF3 as an adaptor

    by Bao-Cun Zhang, Alice Pedersen, Line S. Reinert, Ying Li, Ryo Narita, Manja Idorn, Lili Hu, Morten K. Skouboe, Sirui Li, Muyesier Maimaitili, et al.

    NF-κB is central for activation of immune responses. Cytosolic DNA activates the cGAS–STING pathway to induce type I interferons (IFNs) and signaling through NF-κB, thus instigating host defenses and pathological inflammation. However, the mechanism underlying STING-induced NF-κB activation is unknown. Here we report that STING activates NF-κB in a delayed manner, following exit from the Golgi to endolysosomal compartments. Activation of NF-κB is dependent on the IFN-inducing transcription factor IRF3 but is independent of type I IFN signaling. This activation pattern is evolutionarily conserved in tetrapods. Mechanistically, the monomer IRF3 is recruited to STING pS358, with delayed kinetics relative to IRF3 recruitment to STING pS366, which promotes type I IFN responses. IRF3 engagement with STING pS358 induces trafficking to late endolysosomal compartments, supporting recruitment of TRAF6 and activation of NF-κB. We identify a TRAF6 binding motif in IRF3 that facilitates recruitment of TRAF6. This work defines a signaling surface on STING and a function for IRF3 as an adaptor in immune signaling. These findings indicate that STING signaling to NF-κB is enabled only within a short time window between exit from the Golgi and lysosomal degradation, possibly limiting inflammation under homeostatic and danger-sensing conditions.


  • Open Access

    Activin receptor type IIA/B blockade increases muscle mass and strength, but compromises glycemic control in mice

    by Michala Carlsson, Emma Frank, Joan M. Màrmol, Mona Sadek Ali, Steffen H. Raun, Edmund Battey, Nicoline Resen Andersen, Andrea Irazoki, Camilla Lund, Carlos Henríquez-Olguin, et al.

    Short Purpose: Blocking the Activin receptor type IIA and B (ActRIIA/IIB) has clinical potential to increase muscle mass and improve glycemic control in obesity, cancer, and aging. However, the impact of blocking ActRIIA/IIB on strength, metabolic regulation and insulin action remains unclear. Methods: Here, we investigated the effect of short- (10 mg/kg once, 40h) or long-term (10 mg/kg twice weekly, 21 days) antibody targeting ActRIIA/IIB (αActRIIA/IIBab) in lean and diet-induced obese mice and engineered human muscle tissue. Results: Short-term α ActRIIA/IIB administration in lean mice increased insulin-stimulated glucose uptake in skeletal muscle by 76-105%. Despite this, α ActRIIA/IIB-treated mice exhibited 33% elevated fasting blood glucose and glucose intolerance. Moreover, long-term α ActRIIA/IIB treatment increased average muscle mass (20%) and reduced fat mass (-8%) in obese mice but did not change insulin-stimulated glucose uptake in skeletal muscle or adipose tissue, yet induced marked glucose intolerance, and increased hepatic glucose output in response to pyruvate. Concomitantly, long-term α ActRIIA/IIBab treatment increased strength (30%) in mouse soleus muscle and prevented activin A-induced loss of tissue strength in engineered human muscle tissue. Surprisingly, long-term α ActRIIA/IIBab treatment lowered volitional running (-250%). Conclusion: Our findings demonstrate that, in accordance with human studies, ActRIIA/IIB blockade holds promise for increasing muscle mass, strength, and insulin sensitivity. However, contrary to the improved glycemic control in humans, ActRIIA/IIB blockade in mice causes severe glucose intolerance and lowers voluntary physical activity. Our study underscores the complex metabolic and functional consequences of ActRIIA/IIB blockade, and highlight species differences on glycemic control, which warrant further investigation.

  • Open Access

    The Cryo-EM structure of human CD163 bound to haptoglobin-hemoglobin reveals molecular mechanisms of hemoglobin scavenging

    by Anders Etzerodt, Jakob Hauge Mikkelsen, Morten Torvund-Jensen, Dorle Hennig, Thomas Boesen, Jonas Heilskov Graversen, Søren Kragh Moestrup, Justin M. Kollman, Christian Brix Folsted Andersen

    CD163, a macrophage-specific receptor, plays a critical role in scavenging hemoglobin released during hemolysis, protecting against oxidative effects of heme iron. In the bloodstream, hemoglobin is bound by haptoglobin, leading to its immediate endocytosis by CD163. While haptoglobin’s structure and function are well understood, CD163’s structure and its interaction with the haptoglobin-hemoglobin complex have remained elusive. Here, we present the cryo-electron microscopy structure of the entire extracellular domain of human CD163 in complex with haptoglobin-hemoglobin. The structure reveals that CD163 assembles into trimers (and to some extent dimers), binding haptoglobin-hemoglobin in their center. Key acidic residues in CD163 interact with lysine residues from both haptoglobin and hemoglobin. Calcium-binding sites located near the haptoglobin-hemoglobin interface in CD163 provide explanation for the calcium dependence of the interaction. Furthermore, we show that the interaction facilitating CD163 oligomerization mimics ligand binding and is also calcium dependent. This structural insight into CD163 advances our understanding of its role in hemoglobin scavenging as well as its broader relevance to structurally related scavenger receptors.


  • Trypanosoma brucei Invariant Surface Glycoprotein 75 Is an Immunoglobulin Fc Receptor Inhibiting Complement Activation and Antibody-Mediated Cellular Phagocytosis

    by Jakob Hauge Mikkelsen, Kristian Stødkilde, Maria Pauladòttir Jensen, Annette Gudmann Hansen, Qi Wu, Josefine Lorentzen, Jonas Heilskov Graversen, Gregers Rom Andersen, Robert Andrew Fenton, Anders Etzerodt, et al.

    Various subspecies of the unicellular parasite Trypanosoma brucei cause sleeping sickness, a neglected tropical disease affecting millions of individuals and domestic animals. Immune evasion mechanisms play a pivotal role in parasite survival within the host and enable the parasite to establish a chronic infection. In particular, the rapid switching of variant surface glycoproteins covering a large proportion of the parasite’s surface enables the parasite to avoid clearance by the adaptive immune system of the host. In this article, we present the crystal structure and discover an immune-evasive function of the extracellular region of the T. brucei invariant surface gp75 (ISG75). Structural analysis determined that the ISG75 ectodomain is organized as a globular head domain and a long slender coiled-coil domain. Subsequent ligand screening and binding analysis determined that the head domain of ISG75 confers interaction with the Fc region of all subclasses of human IgG. Importantly, the ISG75–IgG interaction strongly inhibits both activation of the classical complement pathway and Ab-dependent cellular phagocytosis by competing with C1q and host cell FcγR CD32. Our data reveal a novel immune evasion mechanism of T. brucei, with ISG75 able to inactivate the activities of Abs recognizing the parasite surface proteins.


  • Trypanosoma brucei Invariant Surface gp65 Inhibits the Alternative Pathway of Complement by Accelerating C3b Degradation

    by Josefine Lorentzen, Heidi G. Olesen, Annette G. Hansen, Steffen Thiel, Svend Birkelund, Christian B. F. Andersen, Gregers R. Andersen

    Trypanosomes are known to activate the complement system on their surface, but they control the cascade in a manner such that the cascade does not progress into the terminal pathway. It was recently reported that the invariant surface glycoprotein ISG65 from Trypanosoma brucei interacts reversibly with complement C3 and its degradation products, but the molecular mechanism by which ISG65 interferes with complement activation remains unknown. In this study, we show that ISG65 does not interfere directly with the assembly or activity of the two C3 convertases. However, ISG65 acts as a potent inhibitor of C3 deposition through the alternative pathway in human and murine serum. Degradation assays demonstrate that ISG65 stimulates the C3b to iC3b converting activity of complement factor I in the presence of the cofactors factor H or complement receptor 1. A structure-based model suggests that ISG65 promotes a C3b conformation susceptible to degradation or directly bridges factor I and C3b without contact with the cofactor. In addition, ISG65 is observed to form a stable ternary complex with the ligand binding domain of complement receptor 3 and iC3b. Our data suggest that ISG65 supports trypanosome complement evasion by accelerating the conversion of C3b to iC3b through a unique mechanism.


  • Validation of an indirect ELISA assay for assessment of autoantibodies against full-length TRIM21 and its individual domains

    by Marie Louise Næstholt Dahl, Jakob Hauge Mikkelsen, Malene Hvid, Trine-Line Korsholm, Kirstine Overgaard Nielsen, Christian Brix Folsted Andersen, Stinne Greisen, Bent Deleuran

    Anti-SSA-autoantibodies are common in patients with rheumatologic disease, especially Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis. They consist of both autoantibodies towards Ro60 and Ro52, the latter also known as TRIM21. TRIM21 is an intracellular protein consisting of four domains; PRY/SPRY, Coiled-Coil, B-box and RING. The aim of this study was to establish an indirect ELISA detecting autoantibodies towards both the full-length TRIM21 protein and its four domains. We expressed the five constructs, created, and validated indirect ELISA protocols for each target using plasma from anti-SSA positive patients and healthy controls. Our findings were validated to the clinically used standards. We measured significantly higher levels of autoantibodies towards our full-length TRIM21, and the PRY/SPRY, Coiled-Coil and RING domains in patients compared to healthy controls. No significant difference in the level of autoantibodies were detected against the B-box domain. Our setups had a signal to noise ratio in the range of 30 to 184, and an OD between 2 and 3. Readings did not decline using NaCl of 500 mM as wash, affirming the high binding affinity of the autoantibodies measured. Our protocols allow us to further study the different autoantibodies of anti-SSA positive patients. This creates the possibility to stratify our patients into subgroups regarding autoantibody profile and specific pheno- or endotype.


  • Open Access

    Solution Structure of the Cutibacterium acnes-Specific Protein RoxP and Insights Into Its Antioxidant Activity

    by Kristian Stødkilde, Jakob Toudahl Nielsen, Steen Vang Petersen, Bernhard Paetzold, Holger Brüggemann, Frans A. A. Mulder, Christian Brix Folsted Andersen

    Cutibacterium acnes is a predominant bacterium on human skin and is generally regarded as commensal. Recently, the abundantly secreted protein produced by C. acnes, RoxP, was shown to alleviate radical-induced cell damage, presumably via antioxidant activity, which could potentially be harnessed to fortify skin barrier function. The aim of this study was to determine the structure of RoxP and elucidate the mechanisms behind its antioxidative effect. Here, we present the solution structure of RoxP revealing a compact immunoglobulin-like domain containing a long flexible loop which, in concert with the core domain, forms a positively charged groove that could function as a binding site for cofactors or substrates. Although RoxP shares structural features with cell-adhesion proteins, we show that it does not appear to be responsible for adhesion of C. acnes bacteria to human keratinocytes. We identify two tyrosine-containing stretches located in the flexible loop of RoxP, which appear to be responsible for the antioxidant activity of RoxP.


  • Open Access

    Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain

    by Sarah Christine Christensen, Berit Olsen Krogh, Allan Jensen, Christian Brix Folsted Andersen, Søren Christensen, Morten Schallburg Nielsen

    The brain uptake of biotherapeutics for brain diseases is hindered by the blood–brain barrier (BBB). The BBB selectively regulates the transport of large molecules into the brain and thereby maintains brain homeostasis. Receptor-mediated transcytosis (RMT) is one mechanism to deliver essential proteins into the brain parenchyma. Receptors expressed in the brain endothelial cells have been explored to ferry therapeutic antibodies across the BBB in bifunctional antibody formats. In this study, we generated and characterized monoclonal antibodies (mAbs) binding to the basigin receptor, which recently has been proposed as a target for RMT across the BBB. Antibody binding properties such as affinity have been demonstrated to be important factors for transcytosis capability and efficiency. Nevertheless, studies of basigin mAb properties' effect on RMT are limited. Here we characterize different basigin mAbs for their ability to associate with and subsequently internalize human brain endothelial cells. The mAbs were profiled to determine whether receptor binding epitope and affinity affected receptor-mediated uptake efficiency. By competitive epitope binning studies, basigin mAbs were categorized into five epitope bins. mAbs from three of the epitope bins demonstrated properties required for RMT candidates judged by binding characteristics and their superior level of internalization in human brain endothelial cells.